Cargando…
Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial
The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel p...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Chonnam National University Medical School
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794480/ https://www.ncbi.nlm.nih.gov/pubmed/29399567 http://dx.doi.org/10.4068/cmj.2018.54.1.55 |
_version_ | 1783297132331008000 |
---|---|
author | Sim, Doo Sun Jeong, Myung Ho Hong, Young Joon Kim, Ju Han Ahn, Youngkeun Park, Keun Ho Hwang, Sun Ho Kang, Dong Goo Lee, Seung Uk Kim, Joon Woo Park, Jong Pil Rhew, Jay Young Lee, Sang Rok Chae, Jei Keon Yun, Kyeong Ho Oh, Seok Kyu Kang, Won You Kim, Su Hyun Cho, Jang Hyun |
author_facet | Sim, Doo Sun Jeong, Myung Ho Hong, Young Joon Kim, Ju Han Ahn, Youngkeun Park, Keun Ho Hwang, Sun Ho Kang, Dong Goo Lee, Seung Uk Kim, Joon Woo Park, Jong Pil Rhew, Jay Young Lee, Sang Rok Chae, Jei Keon Yun, Kyeong Ho Oh, Seok Kyu Kang, Won You Kim, Su Hyun Cho, Jang Hyun |
author_sort | Sim, Doo Sun |
collection | PubMed |
description | The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel percutaneous coronary intervention (PCI) were divided into 2 groups the ER group (n=288) and the ES group (n=200). The primary endpoint was a composite of major adverse cardiac events (MACE) consisting of death, myocardial infarction, and target vessel revascularization after 12 months. In all patients, the prevalence of diabetes was higher in the ER group (42.7% vs. 31.0%, p=0.009). The rate of post-PCI Thrombolysis in Myocardial Infarction flow grade 3 was higher in the ER group (100.0% vs. 98.0%, p=0.028). There were no between-group differences in the in-hospital, 1-month and 12-month clinical outcomes. In the propensity score matched cohort (n=200 in each group), no differences were observed in the baseline and procedural characteristics. There were no statistical differences in the rates of in-hospital, 1-month and 12-month events (12-month MACE in the ER and ES groups: 6.0% vs. 3.5%, p=0.240, respectively). The safety and efficacy of both versions of ZES were comparable in patients with multivessel disease during a 12-month clinical follow-up. |
format | Online Article Text |
id | pubmed-5794480 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Chonnam National University Medical School |
record_format | MEDLINE/PubMed |
spelling | pubmed-57944802018-02-02 Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial Sim, Doo Sun Jeong, Myung Ho Hong, Young Joon Kim, Ju Han Ahn, Youngkeun Park, Keun Ho Hwang, Sun Ho Kang, Dong Goo Lee, Seung Uk Kim, Joon Woo Park, Jong Pil Rhew, Jay Young Lee, Sang Rok Chae, Jei Keon Yun, Kyeong Ho Oh, Seok Kyu Kang, Won You Kim, Su Hyun Cho, Jang Hyun Chonnam Med J Original Article The Endeavor Resolute® (ER) is a zotarolimus-eluting stent (ZES) with a biocompatible BioLinx polymer. This study prospectively compared the clinical outcomes of 2 versions of ZES, ER and Endeavor Sprint® (ES), in patients with multivessel disease. A total of 488 patients who underwent multivessel percutaneous coronary intervention (PCI) were divided into 2 groups the ER group (n=288) and the ES group (n=200). The primary endpoint was a composite of major adverse cardiac events (MACE) consisting of death, myocardial infarction, and target vessel revascularization after 12 months. In all patients, the prevalence of diabetes was higher in the ER group (42.7% vs. 31.0%, p=0.009). The rate of post-PCI Thrombolysis in Myocardial Infarction flow grade 3 was higher in the ER group (100.0% vs. 98.0%, p=0.028). There were no between-group differences in the in-hospital, 1-month and 12-month clinical outcomes. In the propensity score matched cohort (n=200 in each group), no differences were observed in the baseline and procedural characteristics. There were no statistical differences in the rates of in-hospital, 1-month and 12-month events (12-month MACE in the ER and ES groups: 6.0% vs. 3.5%, p=0.240, respectively). The safety and efficacy of both versions of ZES were comparable in patients with multivessel disease during a 12-month clinical follow-up. Chonnam National University Medical School 2018-01 2018-01-25 /pmc/articles/PMC5794480/ /pubmed/29399567 http://dx.doi.org/10.4068/cmj.2018.54.1.55 Text en © Chonnam Medical Journal, 2018 http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Sim, Doo Sun Jeong, Myung Ho Hong, Young Joon Kim, Ju Han Ahn, Youngkeun Park, Keun Ho Hwang, Sun Ho Kang, Dong Goo Lee, Seung Uk Kim, Joon Woo Park, Jong Pil Rhew, Jay Young Lee, Sang Rok Chae, Jei Keon Yun, Kyeong Ho Oh, Seok Kyu Kang, Won You Kim, Su Hyun Cho, Jang Hyun Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial |
title | Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial |
title_full | Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial |
title_fullStr | Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial |
title_full_unstemmed | Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial |
title_short | Safety and Efficacy of the Endeavor Resolute® Stent in Patients with Multivessel Disease: The HEART (Honam EndeAvor ResoluTe) Prospective, Multicenter Trial |
title_sort | safety and efficacy of the endeavor resolute® stent in patients with multivessel disease: the heart (honam endeavor resolute) prospective, multicenter trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5794480/ https://www.ncbi.nlm.nih.gov/pubmed/29399567 http://dx.doi.org/10.4068/cmj.2018.54.1.55 |
work_keys_str_mv | AT simdoosun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT jeongmyungho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT hongyoungjoon safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT kimjuhan safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT ahnyoungkeun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT parkkeunho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT hwangsunho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT kangdonggoo safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT leeseunguk safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT kimjoonwoo safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT parkjongpil safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT rhewjayyoung safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT leesangrok safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT chaejeikeon safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT yunkyeongho safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT ohseokkyu safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT kangwonyou safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT kimsuhyun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial AT chojanghyun safetyandefficacyoftheendeavorresolutestentinpatientswithmultivesseldiseasethehearthonamendeavorresoluteprospectivemulticentertrial |